For most people living with HIV, treatment has long meant a daily pill containing three medicines. Updated European guidelines now open the door to two-drug treatment for more people. The European AIDS Clinical Society (EACS) presented version 13.1 of its HIV guidelines on November 9 at the HIV Drug Therapy Glasgow 2026 congress, and the changes widen who can be considered for the two-drug pill dolutegravir/lamivudine and for long-acting cabotegravir/rilpivirine injections.

EACS guidelines are written for clinicians in Europe, and they are not US rules. But they are among the most widely followed HIV treatment guides in the world, and they reflect where the evidence is heading. Here is what changed and what it may mean for you.

What changed for the two-drug pill

Dolutegravir/lamivudine (sold as Dovato) combines two HIV medicines in one daily tablet. According to the EACS summary of changes and aidsmap's report from the congress:

• High viral load is no longer a barrier to starting it. Earlier European guidance limited starting dolutegravir/lamivudine to people with a viral load below 500,000 copies. That limit has been removed. aidsmap reports that an analysis of two clinical trials found the combination worked just as well at very high viral loads. The exception is primary (very recent) HIV infection, when a three-drug combination is still advised to bring the virus down quickly and lower the risk of drug resistance.
• A past lamivudine resistance mutation does not automatically rule out switching. People who once developed the M184V mutation were previously discouraged from switching to the two-drug pill. The new guidance says a history of M184V does not necessarily rule out switching for people whose viral load is suppressed, with no sign of resistance to integrase inhibitors and taking their full treatment history into account. Professor Alexandra Calmy of Geneva University Hospital, a member of the guidelines group, said the growing evidence shows the risk of viral rebound in this situation is very low.
• Pregnancy: women who are already taking dolutegravir/lamivudine with a suppressed viral load can stay on it when they become pregnant. It is not recommended as a starting treatment for pregnant women who are not yet on treatment.
• Children: the two-drug pill is now listed as an option for children over two years old who weigh more than 10 kg and have a suppressed viral load, based on the D3/Penta 21 trial.

What changed for long-acting injections

Cabotegravir/rilpivirine is a two-drug treatment given as injections every one or two months (sold in the US as Cabenuva). The updated guidelines make two changes:

• Starting straight with injections: going "direct to inject" is now the preferred approach for most people. A month of oral tablets first (the "oral lead-in") remains optional in selected situations, such as concerns about tolerability.
• Some people who are not yet suppressed: the injections may now be considered as an exceptional option for carefully selected people who struggle to take daily pills, with specialist involvement and close viral load monitoring. aidsmap notes they must have no resistance to either drug and be able to attend consistently for injections and checkups.

You can read how long-acting shots perform outside clinical trials in our coverage of real-world results for long-acting HIV shots.

Other updates worth knowing

• Fewer clinic visits for some people: annual visits may be appropriate for people who are stable and virally suppressed without major other health conditions.
• Older drugs downgraded: regimens based on abacavir and efavirenz moved out of the "alternative" category into a new "other regimens" group. aidsmap links this to concerns about heart risk with abacavir and mental health side effects with efavirenz.
• Sexual health: the guidelines added that syphilis caught while using doxyPEP may show unusual or weaker blood-test (RPR) results, and that meningococcal vaccines are not effective at preventing gonorrhea in people at high risk. For more on what doxyPEP does and does not cover, see our guide to what PrEP and doxyPEP do not protect against.
• Loneliness on the checklist: loneliness and social isolation were added as key topics for clinics to ask about when collecting patient-reported outcomes, along with concerns about memory and thinking.

Why it matters for dating and relationships

Treatment choices are personal, but they can shape everyday life: how many pills are in your bag, how often you see a clinic, and how much space HIV takes up in your week. More options give people more room to find a routine that fits, which is a theme we have covered this week in our report on a weekly HIV pill that meant fewer daily reminders of HIV.

What matters most for partners has not changed. Any treatment that keeps your viral load undetectable means HIV cannot be passed on through sex. That is U=U (Undetectable = Untransmittable), and our explainer covers what U=U means for dating and relationships. Two drugs or three, pill or injection, the goal is the same: staying undetectable.

It is also meaningful that European HIV experts now list loneliness as something clinics should ask about. For many people, stigma can make dating feel isolating. If that sounds familiar, you are not alone, and our guide to dating after an HIV diagnosis may help. Whether and when to tell a partner about your status is your decision, and disclosure laws vary by state. Our guide to HIV disclosure while dating walks through that conversation.

What this does and does not mean

• These are European guidelines. In the United States, clinicians generally follow the HHS guidelines, which are updated separately and may differ in places. We covered the most recent US update in US HIV Guidelines Add Once-Daily Bixlenvo and Back Statins.
• Guidelines are a starting point, not a prescription. Whether two-drug treatment suits you depends on your resistance history, hepatitis B status, other medicines and other health factors that only your care team can weigh.
• Some changes apply to small groups. Using injections when the virus is not yet suppressed is described as an exceptional strategy for carefully selected people, not a routine option.
• Never stop or change HIV treatment on your own. Changes should always be planned with your HIV care provider, with viral load checks afterward.

The bottom line

Updated European HIV guidelines widen who can be considered for two-drug treatment, remove a long-standing viral load limit for starting the two-drug pill, ease switching for some people with past lamivudine resistance, and make starting long-acting injections simpler. Three-drug treatment remains a proven option, and the most important goal is unchanged: an undetectable viral load that protects your health and your partners. If you are curious whether a simpler regimen could work for you, bring it up at your next appointment.

Want to meet people who already understand? Explore HIV dating on MeetPositives.

Sources

• European AIDS Clinical Society. "EACS Guidelines: Summary of Changes from v13.0 to v13.1." 2026.
• aidsmap (Keith Alcorn). "European guidelines widen access to two-drug HIV treatment." HIV Glasgow 2026 coverage, November 12, 2026.
• Marinosci A, et al. Presentation of the updated EACS Guidelines, HIV Drug Therapy Glasgow 2026, November 9, 2026.

This article is for general information only and is not medical or legal advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation. Laws vary by state; for legal questions, talk with a licensed attorney. This article does not recommend or promote any product.